Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Article By:
ChinaBio® Today
Saturday, February 18, 2023 12:20 PM EDT
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of $11 million.
Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
Article By:
ChinaBio® Today
Saturday, May 14, 2022 1:30 PM EDT
Zhaoke Ophthalmology acquired China/Southeast Asia rights for two eyedrop candidates from Visus Therapeutics in a $130 million deal. Meanwhile, Coherus Biosciences returned the US rights to market an Innovent Avastin biosimilar.
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
Article By:
ChinaBio® Today
Saturday, May 7, 2022 2:14 PM EDT
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in biopharma exits over the past year.
Week In Review: Two China Affiliated Biopharmas Raise $585 Million In IPOs
Article By:
ChinaBio® Today
Saturday, November 6, 2021 1:59 PM EDT
LianBio raised $325 million in its Nasdaq IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma also completed a $260 million IPO in Hong Kong.
Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2
$CHRS $MRTX $AKBA $CRVS $IOVA Crvs should be running starting Monday One on one meeting with Richard Miller and Jeffries Co on June 7 Then Lugano on June 17th.